SPORANOX
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Mar 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
SPORANOX by Johnson & Johnson is mechanism of action in vitro studies have demonstrated that itraconazole inhibits the cytochrome p450-dependent synthesis of ergosterol, which is a vital component of fungal cell membranes. Approved for the following fungal infections in immunocompromised, non-immunocompromised patients: blastomycosis, pulmonary and 11 more indications. First approved in 1999.
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SPORANOX is an injectable antifungal medication approved in 1999 by Johnson & Johnson. The specific mechanism of action and therapeutic indications are not documented in available data, but the injectable formulation suggests treatment of systemic or serious fungal infections. As a small-molecule injectable, it likely inhibits fungal cell membrane synthesis.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30% score), indicating potential downsizing or strategic repositioning of the commercial team.
Mechanism of Action
Mechanism of Action In vitro studies have demonstrated that itraconazole inhibits the cytochrome P450-dependent synthesis of ergosterol, which is a vital component of fungal cell membranes.
Worked on SPORANOX at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.